Volume 13, Issue 9b pp. 4051-4060

Quality control for normal liquid-based cytology: Rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection?

Christophe E. Depuydt

Corresponding Author

Christophe E. Depuydt

Laboratory for Clinical Pathology (Labo Lokeren, campus RIATOL), Amerikalei, Antwerp, Belgium

Correspondence to: Christophe DEPUYDT, Laboratory for Clinical Pathology (Labo RIATOL), Amerikalei 62-64, B-2000 Antwerp, Belgium.
Tel.: +32 3 259 0300
Fax: +32 3 216 16 53
E-mail: [email protected]Search for more papers by this author
Marc Arbyn

Marc Arbyn

European Network for Cervical Cancer Screening, Scientific Institute of Public Health, Juliette Wytsmanstraat, Brussels, Belgium

Search for more papers by this author
Ina H. Benoy

Ina H. Benoy

Laboratory for Clinical Pathology (Labo Lokeren, campus RIATOL), Amerikalei, Antwerp, Belgium

Search for more papers by this author
Johan Vandepitte

Johan Vandepitte

Laboratory for Clinical Pathology (Labo Lokeren, campus RIATOL), Amerikalei, Antwerp, Belgium

Search for more papers by this author
Annie J. Vereecken

Annie J. Vereecken

Laboratory for Clinical Pathology (Labo Lokeren, campus RIATOL), Amerikalei, Antwerp, Belgium

Search for more papers by this author
Johannes J. Bogers

Johannes J. Bogers

Laboratory for Clinical Pathology (Labo Lokeren, campus RIATOL), Amerikalei, Antwerp, Belgium

Laboratory of Cell and Tissue Research, Faculty of Medicine, University of Antwerp, Antwerp, Belgium

Search for more papers by this author
First published: 29 January 2010
Citations: 14

Abstract

The objective of this prospective study was to compare the number of CIN2+cases detected in negative cytology by different quality control (QC) methods. Full rescreening, high-risk (HR) human papillomavirus (HPV)-targeted reviewing and HR HPV detection were compared. Randomly selected negative cytology detected by BD FocalPoint™ (NFR), by guided screening of the prescreened which needed further review (GS) and by manual screening (MS) was used. A 3-year follow-up period was available. Full rescreening of cytology only detected 23.5% of CIN2+ cases, whereas the cytological rescreening of oncogenic positive slides (high-risk HPV-targeted reviewing) detected 7 of 17 CIN2+ cases (41.2%). Quantitative real-time PCR for 15 oncogenic HPV types detected all CIN2+ cases. Relative sensitivity to detect histological CIN2+ was 0.24 for full rescreening, 0.41 for HR-targeted reviewing and 1.00 for HR HPV detection. In more than half of the reviewed negative cytological preparations associated with histological CIN2+cases no morphologically abnormal cells were detected despite a positive HPV test. The visual cut-off for the detection of abnormal cytology was established at 6.5 HR HPV copies/cell. High-risk HPV detection has a higher yield for detection of CIN2+ cases as compared to manual screening followed by 5% full review, or compared to targeted reviewing of smears positive for oncogenic HPV types, and show diagnostic properties that support its use as a QC procedure in cytologic laboratories.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.